Portfolio company news

All Group media enquiries should be directed to
Vanessa Maydon, Corporate Affairs Director.

Cinven Partners LLP
Warwick Court
Paternoster Square
London EC4M 7AG

 

Tel: +44 (0)20 7661 3325
Mob: +44 (0)7802 961 902
Email: Vanessa Maydon

Press releases

AMCo
14 July 2015

AMCo acquires Australian company Boucher and Muir

The British-based international niche pharmaceutical business AMCo has acquired the Australian pharmaceutical company, Boucher and Muir (‘BNM’).   

BNM was set up in 1957 and has grown to become a highly successful company with sales in Australia, New Zealand and the Pacific Islands. BNM sells medical products from vaccines to anaesthetics, as well as more typical products such as solid dose tablets and capsules. It also works closely with government health departments in the Pacific Islands. It has an excellent reputation for quality and reliability. AMCo and BNM have been working together for the past ten years, as BNM is one of AMCo’s main distributors for medicines in the region. 

The acquisition of BNM is in keeping with AMCo’s strategy of international expansion into key territories. It will allow AMCo to create a regional commercial centre in Australia, along similar lines to the Nordics regional centre that AMCo created when it acquired Abcur AB in Sweden in December 2013. Earlier this year AMCo created a further regional centre in Dubai to serve the MENA region.

John Beighton, Chief Executive Officer of AMCo said: “Boucher and Muir has been our trusted partner in the Australasian region for the past decade and we are pleased to be able to acquire the company. It has a strong history of supplying niche medicines in the region and we will be looking to build on that as a cornerstone of AMCo’s expansion in Australia, New Zealand and the surrounding geographies.

David Frish, Managing Director of BNM said: “We have had a great partnership with AMCo for the past decade and we are delighted to become part of the AMCo family. I look forward to working more closely with them as part of the team, and to bringing more AMCo niche medicines into the local market.

AMCo currently sells its products in 112 territories worldwide. Since the acquisition of Fucithalmic® from LEO Pharma in April 2013, AMCo has acquired or set up commercial platforms in Ireland, France, Sweden, Benelux, Italy, Dubai and now Australia. AMCo has also established presence in South Africa, Hong Kong and Argentina to manage its regional African, AsiaPac and Latin America businesses respectively.